LB Pharmaceuticals (Nasdaq: LBRX) widens loss as cash reaches $327.8M and trials advance
Rhea-AI Filing Summary
LB Pharmaceuticals reported second quarter 2026 results and a corporate update centered on its lead neuropsychiatric candidate LB-102. The pivotal Phase 3 NOVA-2 trial in schizophrenia is enrolling faster than expected, with topline data now projected in the first half of 2027, followed by a planned pre-NDA FDA meeting in the second half of 2027. Additional Phase 2 trials in bipolar depression and adjunctive major depressive disorder are ongoing or planned, with key readouts expected from 2028–2029.
Liquidity is a major focus: cash, cash equivalents and marketable securities totaled $327.8 million as of June 30, 2026, and together with proceeds from a recent $150.0 million private placement are expected to fund operations beyond the second quarter of 2029 through multiple clinical milestones. The company is using this capital to expand LB-102 into new neuropsychiatric indications.
The investment phase is driving significantly higher spending. Research and development expense rose to $44.1 million in the quarter from $2.4 million a year earlier, contributing to a quarterly net loss of $51.6 million versus $4.9 million in the prior-year period. For the first six months of 2026, net loss was $70.7 million. The balance sheet shows total assets of $361.7 million and stockholders’ equity of $332.3 million as of June 30, 2026, reflecting a well-capitalized but loss-making development-stage profile.
Positive
- Strong liquidity with $327.8 million in cash, cash equivalents and marketable securities plus a recent $150.0 million private placement, expected to fund operations beyond Q2 2029.
- Clinical development de-risking signals: pivotal Phase 3 NOVA-2 trial for LB-102 in schizophrenia now projects topline data in H1 2027, ahead of prior guidance.
- Multiple value-creating catalysts disclosed, including expected topline data from Phase 2 LB-102 trials in bipolar depression in Q1 2028 and adjunctive MDD in the first half of 2029.
Negative
- Loss profile expanded sharply, with Q2 2026 net loss of $51.6 million versus $4.9 million a year earlier, and first-half 2026 net loss of $70.7 million.
- Operating expenses increased substantially, led by research and development of $44.1 million in Q2 2026 compared with $2.4 million in Q2 2025, reflecting heavy cash burn before potential approvals.
8-K Event Classification
Key Figures
Key Terms
topline data readout medical
pivotal Phase 3 medical
pre-NDA meeting regulatory
benzamide antipsychotic medical
negative symptoms of schizophrenia medical
Private Securities Litigation Reform Act of 1995 regulatory
Earnings Snapshot
Company expects cash, cash equivalents, marketable securities and recent $150.0 million private placement proceeds to fund operations beyond the second quarter of 2029.
FAQ
What were LB Pharmaceuticals (LBRX) second quarter 2026 financial results?
How much cash does LB Pharmaceuticals (LBRX) have and what is its runway?
What are the key clinical milestones for LB-102 disclosed by LB Pharmaceuticals (LBRX)?
How did LB Pharmaceuticals (LBRX) operating expenses change in Q2 2026?
What is LB Pharmaceuticals’ (LBRX) balance sheet position as of June 30, 2026?
What therapeutic focus does LB Pharmaceuticals (LBRX) have with LB-102?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (state or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code:
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 2.02 | Results of Operations and Financial Condition. |
On August 11, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit |
Description | |
| 99.1 | Press Release dated August 11, 2026. | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LB PHARMACEUTICALS INC | ||
| By: | /s/ Heather Turner | |
| Heather Turner | ||
| Chief Executive Officer | ||
Dated: August 11, 2026
Exhibit 99.1
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027
Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride
Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expansion, expected to fund operations beyond Q2 2029, through multiple clinical milestones
NEW YORK, August 11, 2026 (GLOBE NEWSWIRE) – LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced financial results for the second quarter ended on June 30, 2026 and provided a corporate update.
“We are taking meaningful steps to maximize the full potential of LB-102, leveraging clinically validated biology with purposeful innovation as the foundation for an expanded pipeline,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “We recently announced a private placement of $150 million with participation from new and existing investors to expand the development of LB-102 into new indications where unmet needs align with the emerging clinical profile of LB-102. We are looking forward to our first pivotal trial readout and recently announced that, based on enrollment in our pivotal NOVA-2 trial in schizophrenia being more rapid than expected, we now project topline data readout in the first half of 2027, ahead of our prior guidance, and plan to schedule a pre-NDA meeting with the FDA soon thereafter in the second half of 2027. We are well positioned to advance multiple clinical programs and continue to expect topline data from our Phase 2 trial of LB-102 in bipolar depression in the first quarter of 2028 as well as data from our Phase 2 trial of LB-102 in adjunctive MDD in the first half of 2029.”
Second Quarter 2026 and Recent Highlights
The Company’s lead asset, LB-102, is a novel benzamide in late-stage clinical development for psychosis and mood disorders. LB-102 has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB-102 in Schizophrenia
| • | Based on enrollment projections in the pivotal Phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 in patients with acute schizophrenia, topline data is expected in the first half of 2027. The Company expects to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027. |
| • | The 52-week open-label safety and tolerability trial (NOVA-3), evaluating the long-term safety and tolerability of LB-102 in patients with stable schizophrenia, is enrolling eligible patients who have completed NOVA-2, as well as de novo patients. |
| • | Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in JAMA Psychiatry. |
LB-102 in Mood Disorders: Bipolar Depression and Adjunctive Treatment of MDD
| • | The Phase 2 ILLUMINATE-1 trial evaluating the efficacy and safety of LB-102 in patients with bipolar 1 depression is enrolling patients, with topline data expected in the first quarter of 2028. |
| • | Initiation of the Phase 2 trial in the adjunctive treatment of MDD is expected in early 2027, with topline data expected in the first half of 2029. |
Corporate Updates
| • | In July 2026, the Company announced a private placement of $150.0 million with participation from new and existing institutional investors. The proceeds are intended to fund expansion of LB-102 into new indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease psychosis/agitation, and for general corporate purposes. |
| • | In June 2026, the Company announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel is a seasoned biotechnology executive with more than 25 years of global development operations experience. |
Financial Results for the Three Months Ended June 30, 2026
| • | Research & Development Expenses: Research and development expenses were $44.1 million for the three months ended June 30, 2026, compared to $2.4 million for the three months ended June 30, 2025. The increase of $41.7 million was primarily due to (i) a $32.1 million increase in expenses primarily related to our Phase 3 clinical trial of LB-102 in the treatment of patients with acute schizophrenia; (ii) a $2.7 million increase in expenses related to the conduct of our Phase 2 clinical trial of LB-102 in the treatment of patients with bipolar depression; (iii) a $2.0 million increase in expenses related to the formulation and production of LB-102 for use in our active and planned clinical trials; (iv) a $4.0 million increase in personnel-related expenses primarily due to an increase in headcount, an increase in termination benefits, and an increase in stock compensation expense related to an option modification; and (v) a $1.3 million increase in preclinical and other direct expenses related to LB-102. |
| • | General & Administrative Expenses: General and administrative expenses were $9.8 million for the three months ended June 30, 2026, compared to $2.4 million for the three months ended June 30, 2025. The increase of $7.3 million was primarily due to (i) a $2.8 million increase in stock-based compensation expense primarily related to stock options granted and repriced in connection with the IPO, new hire grants, and an option modification; (ii) a $2.3 million increase in professional, consulting and public company related expenses; and (iii) a $2.1 million increase in personnel-related expenses primarily due to an increase in headcount. |
| • | Net Loss: Net loss was $51.6 million for the three months ended June 30, 2026, as compared to $4.9 million for the three months ended June 30, 2025. |
| • | Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2026 were approximately $327.8 million, which does not include net proceeds from our $150.0 million private placement in July 2026. Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and marketable securities will support its planned operations beyond the second quarter of 2029. |
Financial Results for the Six Months Ended June 30, 2026
| • | Research & Development Expenses: Research and development expenses were $58.8 million for the six months ended June 30, 2026, compared to $5.8 million for the six months ended June 30, 2025. The increase of $53.0 million was primarily due to (i) a $36.8 million increase in clinical trial expenses related to our Phase 3 trial of LB-102 in the treatment of patients with acute schizophrenia; (ii) a $5.7 million increase related to the conduct of our Phase 2 trial of LB-102 in the treatment of patients with bipolar depression; (iii) a $3.6 million increase in expenses related to the formulation and production of LB-102 for use in our active and planned clinical trials; (iv) a $1.9 million increase in preclinical and other direct expenses related to LB-102; and (v) a $5.0 million increase in personnel-related expenses primarily due to an increase in headcount, an increase in termination benefits, and an increase in stock compensation expense related to an option modification. |
| • | General & Administrative Expenses: General and administrative expenses were $17.2 million for the six months ended June 30, 2026, compared to $5.4 million for the six months ended June 30, 2025. The increase of $11.8 million was primarily due to (i) a $4.4 million increase in stock-based compensation expense primarily related to stock options granted and repriced in connection with the IPO, new hire grants, and an option modification; (ii) a $4.0 million increase in professional, consulting and public company related expenses; and (iii) a $3.6 million increase in personnel-related expenses primarily due to an increase in headcount. |
| • | Net Loss: Net loss was $70.7 million for the six months ended June 30, 2026, as compared to $10.2 million for the six months ended June 30, 2025. |
About LB-102
LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the United States for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the United States, LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5-HT7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to
address multiple dimensions of neuropsychiatric illness. The pivotal Phase 3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a Phase 2 trial of LB-102 in adjunctive treatment of MDD is planned. The Company is also pursuing additional expansion opportunities for LB-102 including predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases.
About LB Pharmaceuticals
LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102; the design, objectives, initiation, timing, progress and results of clinical trials of LB-102, including the pivotal Phase 3 NOVA-2 trial in acute schizophrenia, our open label trial (NOVA-3), the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression and the Phase 2 trial for the adjunctive treatment of MDD; the Company’s plan to pursue any additional indications including negative symptoms of schizophrenia and Alzheimer’s disease psychosis/agitation; anticipated cash runway beyond the second quarter of 2029; continued advancement of LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media and Investor Contact:
Ellen Rose
erose@lbpharma.us
LB Pharmaceuticals Inc
Condensed Statements of Operations
(in thousands, except share and per share data)
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses |
||||||||||||||||
| Research and development |
$ | 44,146 | $ | 2,421 | $ | 58,791 | $ | 5,842 | ||||||||
| General and administrative |
9,769 | 2,438 | 17,228 | 5,446 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating loss |
(53,915 | ) | (4,859 | ) | (76,019 | ) | (11,288 | ) | ||||||||
| Non-operating income |
||||||||||||||||
| Interest income |
2,974 | 177 | 5,824 | 413 | ||||||||||||
| Realized gain on sale of marketable securities, net |
— | — | — | 119 | ||||||||||||
| (Loss) gain on change in fair value of derivative instruments |
(662 | ) | (189 | ) | (462 | ) | 579 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total non-operating income (loss) |
2,312 | (12 | ) | 5,362 | 1,111 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before income tax |
(51,603 | ) | (4,871 | ) | (70,657 | ) | (10,177 | ) | ||||||||
| Income tax provision |
— | — | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
$ | (51,603 | ) | $ | (4,871 | ) | $ | (70,657 | ) | $ | (10,177 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share, basic and diluted |
$ | (1.71 | ) | $ | (13.58 | ) | $ | (2.42 | ) | $ | (28.36 | ) | ||||
| Weighted average shares outstanding used in calculating net loss per share, basic and diluted |
30,137,733 | 358,811 | 29,194,955 | 358,794 | ||||||||||||
LB Pharmaceuticals Inc
Unaudited Condensed Balance Sheets
(In thousands)
| As of | ||||||||
| June 30, 2026 | December 31, 2025 | |||||||
| Cash, cash equivalents and marketable securities |
$ | 327,790 | $ | 295,213 | ||||
| Total assets |
$ | 361,692 | $ | 312,934 | ||||
| Total liabilities |
$ | 29,345 | $ | 11,624 | ||||
| Total stockholders’ equity |
$ | 332,347 | $ | 301,310 | ||||